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High disease burden in myeloablative allogeneic hematopoietic stem cell transplantation is associated with
adverse outcomes in patients with acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS).
Quiescent leukemia stem cells could be induced to enter cell cycle by granulocyte colony-stimulating factor
(G-CSF) administration and become more susceptible to chemotherapy. We report on the outcome of unrelated
cord blood transplantation (CBT) using a conditioning regimen of 12 Gy total body irradiation, G-CSFecom-
bined high-dose cytarabine, and cyclophosphamide in 61 adult patients with AML or advanced MDS not in
remission. With a median follow-up of 97 months, the probability of overall survival and cumulative incidence
of relapse at 7 years were 61.4% and 30.5%, respectively. In multivariate analysis, poor-risk cytogenetics and
high lactate dehydrogenase values at CBT were independently associated with inferior survival. These data
demonstrate that CBT after G-CSFecombined myeloablative conditioning is a promising curative option for
patients with myeloid malignancies not in remission.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION transplantation (CBT) for myeloid malignancies [13-16]. The
The prognoses of patients with acute myelogenous leu-
kemia (AML) and advancedmyelodysplastic syndrome (MDS)
who have not achieved remission after chemotherapy have
been poor. Although allogeneic hematopoietic stem cell
transplantation (allo-HSCT) is the only potentially curative
therapy for such patients, high disease burden has been
reported to be associated with increased relapse or poor
survival rate after allo-HSCT [1-9]. Recently, cord blood (CB)
has been considered an acceptable alternative as a source of
hematopoietic stem cells in unrelated allo-HSCT for adult
patients without HLA-identical related or unrelated donors
[9-16]. In comparison with other sources of allo-HSCT, one of
the main advantages of using CB for patients with a high
disease burden who require urgent transplantation is its
rapid and convenient availability. Because it was shown
that administration of granulocyte colony-stimulating
factor (G-CSF) increased the susceptibility of cell-cyclee
speciﬁc agent cytarabine in leukemia cells in vitro [17], we
administered G-CSFecombined high-dose cytarabine in
myeloablative conditioning for allo-HSCT [18,19] and re-
ported that a G-CSFecombined conditioning regimen pro-
vided better engraftment and survival results in cord bloodedgments on page 400.
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2014 American Society for Blood and Marrow
13.12.555objective of this retrospective study was to conﬁrm the
effects of CBT after G-CSFecombined myeloablative condi-
tioning in adult patients with myeloid malignancies not in
remission and to identify variables inﬂuencing long-term
outcomes.
PATIENTS AND METHODS
Patients and Transplantation Procedures
This retrospective study included 61 consecutive adult patients who
underwent unrelated transplantation using single-unit CB for AML or
advanced MDS not in remission at our institute between 1998 and 2013.
Thirty-two patients were included in our previous study [15,16] and
extended the follow-up. The diagnoses of AML and MDS were made ac-
cording to the World Health Organization classiﬁcation. Advanced MDS was
deﬁned as having refractory anemia with excess blasts type 1 or refractory
anemia with excess blasts type 2 by World Health Organization classiﬁca-
tion. Myeloid malignancies not in remission were deﬁned as more than 5%
blasts in the bonemarrow (BM), or circulating blasts in peripheral blood (PB)
or central nervous system. The cytogenetic subgroups were deﬁned ac-
cording to the Southwest Oncology Group/Eastern Cooperative Oncology
Group criteria for AML [20] and International Prognostic Scoring System
criteria for MDS [21]. All patients received 12 Gy total body irradiation (TBI)
in 4 divided fractions on days 8 and 7, cytarabine on days 5 and 4
(total dose 12 g/m2, and 3 g/m2 every 12 hours for 2 days) with 5 mg/kg
G-CSF (lenograstim) from 12 hours before the ﬁrst dose of cytarabine to the
end of cytarabine dosing, and cyclophosphamide (total dose 120 mg/kg) on
days 3 and 2 [15,16]. Fifty-eight patients received cyclosporine (CSP)
(3 mg/kg/day) with a short course of methotrexate (15 mg/m2 on day þ1
and 10mg/m2 on daysþ3 andþ6), and 3 patients received CSP only as graft-
versus-host disease (GVHD) prophylaxis. CB units were obtained from the
Japanese Cord Blood Bank Network. Donor-recipient HLA-matching status
was based on antigen level HLA-A and -B and on allele level HLA-DRB1
typing. All patients received similar supportive care and CB units wereTransplantation.
Table 1
Characteristics of Patients, Cord Blood Units, and Transplantation
Characteristic Value
No. of patients 61
Sex
Male 36 (59)
Female 25 (41)
Age, median (range), yr 41 (18-55)
CMV serostatus
Positive 54 (86)
Negative 7 (11)
Disease type
De novo AML 24 (39)
AML secondary to MDS 24 (39)
Advanced MDS* 13 (21)
Cytogeneticsy
Good 1 (2)
Intermediate 27 (44)
Poor 30 (49)
Unknown 3 (5)
Bone marrow blasts at CBT, median (range), % 17.7 (1.4-86.0){
< 25% 39
 25% 22
Peripheral blood blasts at CBT, median (range), % 6.5 (0-68.5)
Absent 12
Present 49
LDH at CBT
 ULN 41 (67)
> ULN 20 (33)
Disease status at CBTz
Untreated 31 (51)
Primary refractory 14 (23)
Refractory relapse 16 (26)
Time from diagnosis to CBT, median (range), mo 7 (1-219)
Conditioning regimen
TBI12GyþAra-C/G-CSFþCY 61
GVHD prophylaxis
CyclosporineAþmethotrexate 58 (95)
CyclosporineA 3 (5)
Number of nucleated cells, median (range), 107/kg 2.43 (1.32-5.50)
Number of CD34þcells, median (range), 105/kg 1.03 (.21-2.27)
HLA disparitiesx
1 13 (21)
2 32 (52)
3 14 (22)
4 2 (3)
CMV indicates cytomegalovirus; AML, acute myelogenous leukemia; MDS, myelodysplastic syndrome; CBT, cord blood transplantation; LDH, lactate dehy-
drogenase; ULN, upper limit of normal; TBI, total body irradiation; Ara-C, cytosine arabinoside; G-CSF, granulocyte colony-stimulating factor; CY, cyclophos-
phamide; GVHD, graft-versus-host disease; HLA, human leukocyte antigen.
Data presented are n (%) unless otherwise indicated.
* Advanced MDS are deﬁned as having refractory anemia with excess blasts-1 (RAEB-1) or RAEB-2 by WHO criteria.
y The cytogenetic subgroups according to the Southwest Oncology Group/Eastern Cooperative Oncology Group criteria for AML and International Prognostic
Scoring System criteria for MDS.
z Untreated was deﬁned as no treatment before conditioning regimen, indicating that the majority of patients with AML secondary to MDS or advanced MDS
received CBT as an up-front treatment. Primary refractory was deﬁned as failure to achieve complete remissionwith induction chemotherapy. Refractory relapse
was deﬁned as failure to achieve complete remission with salvage chemotherapy after ﬁrst or subsequent relapse.
x The number of HLA disparities, deﬁned as the low resolution for HLA-A and -B and the high resolution for HLA-DRB1.
{ The 5 patients with less than 5% blasts in the bone marrow included circulating blasts in peripheral blood (n ¼ 3) or central nervous system (n ¼ 2).
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Institute of Medical Science, University of Tokyo approved this study. This
study was conducted in accordance with the Declaration of Helsinki.End Points and Statistical Analysis
The primary study end point was overall survival (OS), deﬁned as time
from the date of transplantation to the date of death or last contact. Sec-
ondary end points were relapse, including disease progression before
engraftment; transplantation-related mortality (TRM); neutrophil and
platelet engraftment; acute graft-versus-host disease (aGVHD); and chronic
GVHD (cGVHD). Relapse was deﬁned as morphologic evidence of disease in
PB, BM, or extramedullary sites. TRMwas deﬁned as death during remission.
Neutrophil engraftment was deﬁned as the ﬁrst of 3 consecutive days during
which the absolute neutrophil count was at least .5  109/L. Platelet
engraftment was achieved on the ﬁrst of 3 days when the platelet count was
higher than 50  109/L without transfusion support. Both aGVHD and
cGVHD were graded according to the previously published criteria [22,23].The incidence of aGVHDwas evaluated in all engrafted patients, whereas the
incidence of cGVHD was evaluated in engrafted patients surviving more
than 100 days.
The probability of OS was estimated according to the Kaplan-Meier
method, and the groups were compared using the log-rank test. The prob-
abilities of relapse, TRM, neutrophil and platelet engraftment, and acute and
chronic GVHD were estimated based on a cumulative incidence method to
accommodate competing risks [24]. Multivariate analysis was performed
with a Cox proportional hazard model adjusted for OS and Fine and Gray
proportional hazards model for relapse [25]. The following variables were
considered: age (< 45 versus  45 years), disease type (de novo AML versus
AML secondary to MDS versus advanced MDS), cytogenetic risk (other than
poor versus poor), proportion of blasts in BM (< 25 versus  25%), the
presence of blasts in PB (absent versus present), lactate dehydrogenase
(LDH) at CBT ( upper limit of normal versus > upper limit of normal),
disease status at CBT (untreated versus primary refractory versus refractory
relapse), cord blood nucleated cell count (< 2.5 versus  2.5  107/kg),
and HLA disparities based on antigen level HLA-A and -B and allele level
T. Konuma et al. / Biol Blood Marrow Transplant 20 (2014) 396e401398HLA-DRB1 ( 2 versus 3). All statistical analyses were performedwith EZR
(Saitama Medical Center, Jichi Medical University, Saitama, Japan), a
graphical user interface for R 2.13.0 (R Foundation for Statistical Computing,
Vienna, Austria) [26]. P< .05 was considered signiﬁcant. Analysis of datawas
performed in August 2013.RESULTS
Patient and CB unit characteristics are shown in Table 1.
The median age was 41 years (range, 18 to 55 years), the
median number of nucleated cells was 2.43  107/kg (range,
1.32 to 5.50  107/kg), and the median number of CD34þ
cells was 1.03  105/kg (range, .21 to 2.27  105/kg). Disease
types were de novo AML in 24 patients, AML secondary to
MDS in 24, and advanced MDS in 13. The majority of patients
with de novo AML with multilineage dysplasia (n ¼ 2), AML
secondary to MDS (n ¼ 19), or advanced MDS (n ¼ 10)
received CBT as an up-front treatment, which was classiﬁed
as untreated group (n ¼ 31). Among patients with primary
refractory status (n ¼ 14), 3 patients received CBT after the
ﬁrst cycle of induction chemotherapy. The median number of
prior chemotherapy treatments before CBT for primary re-
fractory status was 3 (range, 1 to 5). The median time from
diagnosis to CBT was 7 months (range, 1 to 219 months), and
the median period of follow-up for survivors after CBT was
97 months (range, 5 to 181 months).
The cumulative incidence of neutrophil recoverywas 93.4%
(95% conﬁdence interval [CI], 81.0% to 97.8%) at 60 days after
CBT with a median time to achieve greater than .5  109/L
neutrophils of 22 days (range, 18 to 41 days). Disease pro-
gression before engraftment occurred in 2 patients. The cu-
mulative incidence of platelet recovery was 78.7% (95% CI,
65.7% to 87.2%) at 100 days after CBT with a median time to an
untransfused platelet count greater than 50 109/L of 50 days
(range, 30 to 179 days). The cumulative incidences of grade II
to IV acute GVHD and extensive chronic GVHD were 62.3%
(95% CI, 48.7% to 73.2%) at 100 days and 32.9% (95% CI, 21.4% to
44.9%) at 3 years after CBT, respectively. The probability of
OS at 7 years was 61.4% (95% CI, 47.1% to 72.9%). The cumu-
lative incidence of relapse at 7 years was 30.5% (95% CI, 19.2%
to 42.6%). The cumulative incidence of TRM at 100 days and at
1 yearwas 6.6% (95% CI, 2.1% to 14.7%) and 8.2% (95% CI, 3.0% to
16.9%), respectively (Figure 1).
In multivariate analysis, poor-risk cytogenetics (hazard
ratio [HR], 7.14; 95% CI, 2.33 to 21.80; P < .001) and high LDH
value (HR, 4.00; 95% CI, 1.33 to 12.07; P ¼ .013) were asso-
ciated with inferior survival (Figure 2, Table 2). De novo AML
(HR, 9.66; 95% CI, 1.06 to 87.75; P ¼ .044), primary refractory
status at CBT (HR, 6.47; 95% CI, 1.86 to 22.51; P ¼ .003), and
high LDH value (HR, 3.75; 95% CI, 1.11 to 12.57; P¼ .032) were
associated with an increased relapse incidence (Table 3,
Supplemental Figure 1). In contrast, the proportion of blastsFigure 1. Probability of overall survival and cumulative incidences of relapse and tr
survival (A), relapse (B), and transplantation-related mortality (C) in 61 patients with
CBT.in BM and the presence of blasts in PB did not show any
impact on survival and relapse incidence.DISCUSSION
Previous reports have suggested that the only potentially
curative therapy for patients with myeloid malignancies not
in remission is allo-HSCT. However, the incidence of relapse
has been reported to be high, and several reports showed
long-term survival rates of only 10% to 30% [1-6]. Several
factors, including blasts in BM or PB, cytogenetics, and donor
availability, have been associated with outcome. In this study,
poor-risk cytogenetics and high LDH value were signiﬁcantly
associated with inferior OS. De novo AML, primary refractory
status, and high LDH value were associated with increased
relapse. However, we found no impact of disease burden on
survival and relapse. In fact, several retrospective studies did
not show any advantage of induction chemotherapy before
allo-HSCT to reduce the disease burden for patients with
advanced MDS or AML secondary to MDS [27-29]. Therefore,
the majority of patients with advanced MDS or AML sec-
ondary to MDS received G-CSFecombined myeloablative
conditioning followed by CBT without prior induction
chemotherapy in our institute.
After physicians have decided that allo-HSCT is appro-
priate for patients withmyeloidmalignancy not in remission,
the elective timing of the transplantation is the main
advantage of CBT. In fact, CBT timing is decided depending on
the patient’s conditions, such as control of infection and
disease burden. Such elective timing of CBT might have
contributed to disease burden not being shown to inﬂuence
outcome in our study. On the other hand, the use of CB as a
source of hematopoietic stem cells could offer the opportu-
nity for patients to receive allo-HSCT without related or
unrelated donors. Moreover, the lower incidence of severe
GVHD without compromising graft-versus-leukemia effects
in CBTmay also have contributed to long-term survival in our
study.
Relapse is the most important cause of treatment failure
after allo-HSCT, particularly in patients with myeloid malig-
nancies not in remission. This is mainly due to the residual
leukemic cells that have escaped the cytotoxic effect of con-
ditioning before transplantation. To reduce disease relapse,
the role of a more intense conditioning regimen has been
analyzed extensively [30]. Since chemosensitization of leu-
kemia cells with G-CSF enhances the cytotoxicity of the
cell-cycleespeciﬁc agent cytarabine [17], we administered
G-CSFecombined high-dose cytarabine in the standard con-
ditioning regimen of TBI/cyclophosphamide. The clinical
efﬁcacy of concomitant use of G-CSF with chemotherapy has
remained controversial in newly diagnosed or relapsed re-
fractory AML and MDS [31,32]. Recently, Pabst et al. reportedansplant-related mortality after G-CSFecombined myeloablative CBT. Overall
AML or advanced MDS not in remission after G-CSFecombined myeloablative
Table 2
Univariate and Multivariate Analysis of Prognostic Factors for Survival
Variable Univariate Analysis Multivariate Analysis
Number 7-year OS (95% CI) P Hazard Ratio* 95% CI P
Age
< 45 years 36 63.5 (44.1-77.7) 1
 45 25 58.7 (36.7-75.4) .555 .69 .25-1.86 .464
Disease type
Advanced MDS 13 59.3 (27.5-81.0) 1
AML secondary to MDS 24 74.4 (51.6-87.6) .58 .13-2.54 .471
De novo AML 24 47.4 (23.0-68.4) .234 .97 .18-5.16 .978
Cytogeneticsy
Other than poor 31 80.3 (61.3-90.6) 1
Poor 30 38.9 (18.8-58.6) .002 7.14 2.33-21.80 <.001
Bone marrow blasts at CBT, %
< 25 39 58.0 (40.8-71.8) 1
 25 22 68.2 (41.2-84.7) .297 .59 .16-2.09 .418
Peripheral blood blasts at CBT
Absent 12 66.7 (33.7-86.0) 1
Present 49 60.2 (44.0-73.1) .983 1.18 .34-4.10 .787
LDH value at CBT
 ULN 41 67.4 (48.9-80.4) 1
> ULN 20 50.0 (27.1-69.2) .147 4.00 1.33-12.07 .013
Disease status at CBT
Untreated 31 71.1 (50.1-84.5) 1
Primary refractory 14 50.0 (22.9-72.2) 2.76 .78-9.77 .114
Refractory relapse 16 50.0 (20.2-74.1) .234 1.75 .30-10.22 .530
Number of nucleated cells, 107/kg
 2.5 29 59.2 (37.9-75.3) 1
< 2.5 32 64.1 (44.3-78.4) .989 .99 .38-2.58 .989
HLA disparitiesz
 2 45 60.3 (43.7-73.4) 1
 3 16 65.0 (35.1-83.7) .597 .98 .30-3.18 .975
MDS indicates myelodysplastic syndrome; AML, acute myelogenous leukemia; CBT, cord blood transplantation; LDH, lactate dehydrogenase; ULN, upper limit of
normal; HLA, human leukocyte antigen; OS, overall survival; CI, conﬁdence interval.
* Hazards ratio for overall mortality.
y The cytogenetic subgroups according to the Southwest Oncology Group/Eastern Cooperative Oncology Group criteria for AML and International Prognostic
Scoring System criteria for MDS.
z The number of HLA disparities deﬁned as the low resolution for HLA-A and -B and the high resolution for HLAeDRB1.
Figure 2. Adjusted probabilities of overall survival in 61 patients with AML and advanced MDS not in remission after G-CSFecombined myeloablative CBT. The
adjusted probabilities of overall survival grouped according to the disease type (A), cytogenetic risk (B), the proportion of blasts in bone marrow (BM) (C), the
presence of blasts in peripheral blood (PB) (D), the lactate dehydrogenase (LDH) value at cord blood transplantation (CBT) (E), and disease status at CBT (F).
Multivariate analysis for overall survival is shown in Table 2.
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Table 3
Univariate and Multivariate Analysis of Prognostic Factors for Relapse
Variable Univariate Analysis Multivariate Analysis
Number 7-year Relapse (95% CI) P Hazard Ratio 95% CI P
Age
< 45 36 29.3 (15.0-45.2) 1
 45 25 32.0 (14.9-50.6) .567 1.62 .50-5.17 .420
Disease type
Advanced MDS 13 7.7 (.4-30.5) 1
AML secondary to MDS 24 29.8 (12.9-49.0) 4.37 .38-49.80 .230
De novo AML 24 43.4 (22.4-62.7) .096 9.66 1.06-87.75 .044
Cytogenetics*
Other than poor 31 23.0 (9.9-39.2) 1
Poor 30 38.2 (20.5-55.7) .163 2.33 .90-5.97 .078
Bone marrow blasts at CBT, %
< 25 39 26.0 (13.3-40.6) 1
 25 22 39.2 (18.0-59.9) .397 1.72 .57-5.16 .330
Peripheral blood blasts at CBT
Absent 12 16.7 (2.3-42.8) 1
Present 49 33.8 (20.6-47.4) .309 3.08 .40-23.70 .280
LDH value at CBT
 ULN 41 25.6 (13.1-40.1) 1
> ULN 20 40.0 (18.5-60.8) .240 3.75 1.11-12.57 .032
Disease status at CBT
Untreated 31 17.8 (6.3-34.1) 1
Primary refractory 14 50.0 (21.4-73.3) 6.47 1.86-22.51 .003
Refractory relapse 16 37.5 (14.5-60.7) .043 1.36 .26-7.05 .71
Number of nucleated cells, 107/kg
 2.5 29 35.5 (18.3-53.1) 1
< 2.5 32 25.3 (11.7-41.5) .525 .54 .14-2.12 .380
HLA disparitiesy
 2 45 34.0 (20.4-48.1) 1
 3 16 20.3 (4.5-43.9) .306 .53 .11-2.49 .420
MDS indicates myelodysplastic syndrome; AML, acute myelogenous leukemia; CBT, cord blood transplantation; LDH, lactate dehydrogenase; ULN, upper limit of
normal; HLA, human leukocyte antigen; CI, conﬁdence interval.
* The cytogenetic subgroups according to the Southwest Oncology Group/Eastern Cooperative Oncology Group criteria for AML and International Prognostic
Scoring System criteria for MDS.
y The number of HLA disparities deﬁned as the low resolution for HLA-A and -B and the high resolution for HLAeDRB1.
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G-CSF with escalated-dose, but not with conventional-dose
cytarabine [31]. In the setting of allo-HSCT, the conditioning
regimen consisting of G-CSFecombined high-dose cytarabine
and TBI 12 Gy was feasible and might reduce post-
transplantation relapse in patients with AML [18,19]. The
presence of quiescent leukemia stem cells (LSCs), which are
thought to be resistant to chemotherapy, might contribute to
relapse after treatment. Recently, a xenograft model
demonstrated that cytarabinewith G-CSF recruited quiescent
LSCs into a phase of the cell cycle, leading to enhanced
elimination of LSCs within the niche [33]. This effect might
have contributed to reduced relapse in our study. Although
these ﬁndings should be conﬁrmed in prospective studies,
the combination of G-CSFecombined myeloablative condi-
tioning with CBT offered a promising curative option for
patients with myeloid malignancies not in remission.
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